Completed PHASE1 INTERVENTIONAL 2-arm NCT02902289

Bioequivalence Study of Ibuprofen 200 mg/5 mL Oral Suspension vs. MOMENT 200 mg Coated Tablet

Bioequivalence Study of a New Formulation of Ibuprofen 200 mg/5 mL Oral Suspension vs. the Reference Product MOMENT 200 mg Coated Tablet in Healthy Volunteers

Sponsor: Aziende Chimiche Riunite Angelini Francesco S.p.A

Conditions Healthy

Interventions Ibuprofen 200 mg/5 mL oral suspension MOMENT 200 mg coated tablet

Updated 5 times since 2017 Last updated: Sep 12, 2016 Started: Jun 30, 2016 Primary completion: Jul 31, 2016 Completion: Jul 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02902289, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by Aziende Chimiche Riunite Angelini Francesco S.p.A, it has been updated 5 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jun 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Aziende Chimiche Riunite Angelini Francesco S.p.A
Cross Research S.A.

Data source: Aziende Chimiche Riunite Angelini Francesco S.p.A

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Arzo, Switzerland